Original Research

A randomized Phase II clinical study of combining panitumumab and bevacizumab, plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) compared with FOLFIRI alone as second-line treatment for patients with metastatic colorectal cancer and KRAS mutation

Liu YG, Luan LJ, Wang XL

OncoTargets and Therapy 2015, 8:1061-1068

Published Date: 14 May 2015